Abstract 236P
Background
This study aimed to determine the changes to body composition and the risk of adverse effects associated with chemotherapy in patients with advanced urothelial carcinoma (UC). The study also investigated whether bioimpedance analysis (BIA) is an effective method for diagnosing body composition.
Methods
We prospectively evaluated the body composition of 60 patients with locoregional muscle invasive (≥ T2 and N0-2M0) or metastatic UC between April 2021 and June 2023 at the Department of Urology, Juntendo Nerima Hospital, Tokyo, Japan. Body composition was evaluated using multifrequency BIA at baseline and during chemotherapy. The change in body composition was compared between before and during chemotherapy, and the incidence of adverse events was also determined.
Results
Twelve of the 60 patients enrolled in the study failed to complete their planned chemotherapy regimens or the chemotherapy regimen was discontinued or changed due to adverse events or problems related to underlying cancer. The patients who discontinued their treatment were significantly older and had a low muscle mass and a low skeletal muscle index. To assess the time-course changes in the body composition of the 41 patients who underwent chemotherapy, BIA was performed before each cycle. Chemotherapy-associated changes included a reduction in body weight 1.3% (±0.6%) and a decrease in fat mass 6.4% (±3.4%), while muscle mass did not change 0 .0% (±0.8%) between each cycle. Patients, aged 75 years or younger, had a more significant loss of muscle mass than older patients with a low muscle mass at baseline. (2.3% ± 1.0 % vs -1.4% ±1.1%, p=0.033).
Conclusions
BIA may be used as a method of nutrition and muscle assessment for pretreatment risk stratification of patients with advanced UC treated with chemotherapy. Moreover, our findings suggest that elderly patients with a low muscle mass may have trouble completing their chemotherapy course. Furthermore, chemotherapy is associated with changes in body composition which may lead to a loss of muscle mass in non-elderly patients.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
426P - Characterization of a novel comprehensive genomic profiling test with better detection of heterozygous deletions and gene fusions
Presenter: ryouta kakuta
Session: Poster Display
Resources:
Abstract
427P - Real-world performance of a comprehensive next-generation sequencing (NGS) panel for patients (pts) with solid tumors from Asia and the Middle East (AME)
Presenter: Nitesh Rohatgi
Session: Poster Display
Resources:
Abstract
428P - What do women want to see in a personalized breast cancer risk report? A qualitative study of Asian women of two countries
Presenter: Faustina Audrey Agatha
Session: Poster Display
Resources:
Abstract
429P - Clinical utility and outcomes of liquid biopsy-based next generation sequencing in identification of actionable genomic mutations in solid malignancy: A single center retrospective study in the Philippines
Presenter: Omar Maaño
Session: Poster Display
Resources:
Abstract
436P - Chemotherapy-induced hand-foot syndrome, comparative efficacy and safety of pharmacological prophylaxis: Systematic review and network meta-analysis
Presenter: Anand Srinivasan
Session: Poster Display
Resources:
Abstract
437P - A randomized single blinded phase II trial comparing efficacy and quality of life of topical aloe vera gel plus urea cream versus urea cream alone for prevention of hand-foot syndrome in cancer patients receiving capecitabine
Presenter: Lucksika Wanichtanom
Session: Poster Display
Resources:
Abstract
438P - A novel treatment for immune checkpoint inhibitor-related myocarditis
Presenter: Takahiro Niimura
Session: Poster Display
Resources:
Abstract
439P - Randomized controlled trial evaluating efficacy of topical urea-based cream for capecitabine-associated hand-foot syndrome prevention
Presenter: Concord Wongkraisri
Session: Poster Display
Resources:
Abstract
440P - Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic
Presenter: TIKUMPORN PORNWISETSIRIKUL
Session: Poster Display
Resources:
Abstract
441P - The prophylactic efficacy of telpegfilgrastim, a Y-shape branched pegylated G-CSF in patient with chemotherapy-induced neutropenia: A multicenter, randomized phase III study
Presenter: Xinshuai Wang
Session: Poster Display
Resources:
Abstract